Chromatin-modifying agents in anti-cancer therapy

Biochimie

Volumn 94, Issue 11, 2012, Pages 2264-2279

  Seidel, Carole ^a   Florean, Cristina ^a   Schnekenburger, Michael ^a   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

Anti cancer therapy; Clinical trials; Combinatory treatments; DNMT; Epigenetic inhibitors; HDAC

Indexed keywords

2' DEOXY 5,6 DI HYDRO 5 AZACYTIDINE; 2' DEOXY N4 [2 (4 NITROPHENYL)ETHOXYCARBONYL] 5 AZACYTIDINE; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CAFFEIC ACID; CHROMATIN MODIFYING AGENT; CURCUMIN; DAIZDEIN; DISULFIRAM; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; FLUCYTOSINE DEOXYRIBOSIDE; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; KP 1212; MAHANINE; MG 98; N PHTHALOYLTRYPTOPHAN; NANAOMYCIN A; PARTHENOLIDE; PROCAINAMIDE; PROCAINE; ROMIDEPSIN; SGI 1027; SGI 110; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER REGRESSION; CHROMATIN STRUCTURE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLON CANCER; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MODIFICATION; DRUG EFFICACY; EPIGENETICS; FEVER; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HYPERBILIRUBINEMIA; INFECTION; KIDNEY CANCER; LEUKOPENIA; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PNEUMONIA; PROSTATE CANCER; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 84867402272     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.05.012     Document Type: Review

References (232)

1. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
2. S.L. Berger The complex language of chromatin regulation during transcription Nature 447 2007 407 412
3. T. Karius, M. Schnekenburger, M. Dicato, and M. Diederich MicroRNAs in cancer management and their modulation by dietary agents Biochem. Pharmacology 83 12 2012 1591 1601
4. M. Schnekenburger, M. Diederich, Epigenetics offer new Horizons for colorectal cancer prevention, current colorectal cancer report (2012).
5. C. Florean, M. Schnekenburger, C. Grandjenette, M. Dicato, and M. Diederich Epigenomics of leukemia: from mechanisms to therapeutic applications Epigenomics 3 2011 581 609
6. A. Portela, and M. Esteller Epigenetic modifications and human disease Nat. Biotechnol. 28 2010 1057 1068
7. B.O. Van Emburgh, and K.D. Robertson Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants Nucleic Acids Research 39 2011 4984 5002
8. S.K. Ooi, A.H. O'Donnell, and T.H. Bestor Mammalian cytosine methylation at a glance J. Cell Science 122 2009 2787 2791
9. E.L. Walton, C. Francastel, and G. Velasco Maintenance of DNA methylation: Dnmt3b joins the dance Epigenetics 6 2011
10. K.D. Robertson DNA methylation and human disease Nat. Rev. Genet. 6 2005 597 610
11. Y. Kanai, and S. Hirohashi Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state Carcinogenesis 28 2007 2434 2442
12. S. Mizuno, T. Chijiwa, T. Okamura, K. Akashi, Y. Fukumaki, Y. Niho, and H. Sasaki Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia Blood 97 2001 1172 1179
13. M.J. Hoffmann, R. Engers, A.R. Florl, A.P. Otte, M. Muller, and W.A. Schulz Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer Cancer Biol. Ther. 6 2007 1403 1412
14. T. Karius, M. Schnekenburger, J. Ghelfi, J. Walter, M. Dicato, and M. Diederich Reversible epigenetic fingerprint-mediated glutathione-S-transferase P1 gene silencing in human leukemia cell lines Biochem. Pharmacol. 81 2011 1329 1342
15. J. Ren, B.N. Singh, Q. Huang, Z. Li, Y. Gao, P. Mishra, Y.L. Hwa, J. Li, S.C. Dowdy, and S.W. Jiang DNA hypermethylation as a chemotherapy target Cell. Signalling 23 2011 1082 1093
16. S. Amatori, I. Bagaloni, D. Viti, and M. Fanelli Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma Lung Cancer 71 2011 113 115
17. M. Schnekenburger, C. Grandjenette, J. Ghelfi, T. Karius, B. Foliguet, M. Dicato, and M. Diederich Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy Biochem. Pharmacol. 81 2011 364 378
18. N.J. Yogelzang, J.E. Herndon 2nd, C. Cirrincione, D.C. Harmon, K.H. Antman, J.M. Corson, Y. Suzuki, M.L. Citron, and M.R. Green Dihydro-5- azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B Cancer 79 1997 2237 2242
19. M. Matousova, I. Votruba, M. Otmar, E. Tloustova, J. Gunterova, and H. Mertlikova-Kaiserova 2 -deoxy-5,6-dihydro-5-azacytidine - a less toxic alternative of 2 -deoxy-5-azacytidine: a comparative study of hypomethylating potential Epigenetics 6 2011 769 776
20. C. Champion, D. Guianvarc'h, C. Senamaud-Beaufort, R.Z. Jurkowska, A. Jeltsch, L. Ponger, P.B. Arimondo, and A.L. Guieysse-Peugeot Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine PLoS One 5 2010 e12388
21. M. Chen, D. Shabashvili, A. Nawab, S.X. Yang, L. Dyer, K.D. Brown, M. Hollingshead, K.W. Hunter, F.J. Kaye, S.N. Hochwald, V.E. Marquez, P.S. Steeg, and M. Zajac-Kaye DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer Mol. Cancer Ther. 2011
22. J.H. Beumer, J.L. Eiseman, R.A. Parise, E. Joseph, J.L. Holleran, J.M. Covey, and M.J. Egorin Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice Clin. Cancer Res. 12 2006 7483 7491
23. H.M. Byun, S.H. Choi, P.W. Laird, B. Trinh, M.A. Siddiqui, V.E. Marquez, and A.S. Yang 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1 Cancer Letters 266 2008 238 248
24. J.C. Chuang, S.L. Warner, D. Vollmer, H. Vankayalapati, S. Redkar, D.J. Bearss, X. Qiu, C.B. Yoo, and P.A. Jones S110, a 5-Aza-2'-deoxycytidine- containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth Mol. Cancer Ther. 9 2010 1443 1450
25. W.J. Huang, Y.C. Liang, S.E. Chuang, L.L. Chi, C.Y. Lee, C.W. Lin, A.L. Chen, J.S. Huang, C.J. Chiu, C.F. Lee, C.Y. Huang, and C.N. Chen NBM-HD-1: a novel histone deacetylase inhibitor with anticancer activity Evid Based. Complementary Alternat. Med.: ECAM 2012 2012 781417
26. M.Z. Fang, Y. Wang, N. Ai, Z. Hou, Y. Sun, H. Lu, W. Welsh, and C.S. Yang Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines Cancer Res. 63 2003 7563 7570
27. M. Pandey, S. Shukla, and S. Gupta Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells J. International Du Cancer Int. J. Cancer 126 2010 2520 2533
28. V. Nandakumar, M. Vaid, and S.K. Katiyar (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells Carcinogenesis 32 2011 537 544
29. J.C. Chuang, C.B. Yoo, J.M. Kwan, T.W. Li, G. Liang, A.S. Yang, and P.A. Jones Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine Mol. Cancer Ther. 4 2005 1515 1520
30. C. Stresemann, B. Brueckner, T. Musch, H. Stopper, and F. Lyko Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines Cancer Res. 66 2006 2794 2800
31. C.S. Yang, H. Wang, G.X. Li, Z. Yang, F. Guan, and H. Jin Cancer prevention by tea: evidence from laboratory studies Pharmacol. Res.: Official J. Italian Pharmacol. Soc. 64 2011 113 122
32. A. Villar-Garea, M.F. Fraga, J. Espada, and M. Esteller Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells Cancer Res. 63 2003 4984 4989
33. X. Lin, K. Asgari, M.J. Putzi, W.R. Gage, X. Yu, B.S. Cornblatt, A. Kumar, S. Piantadosi, T.L. DeWeese, A.M. De Marzo, and W.G. Nelson Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide Cancer Res. 61 2001 8611 8616
34. P. Zambrano, B. Segura-Pacheco, E. Perez-Cardenas, L. Cetina, A. Revilla-Vazquez, L. Taja-Chayeb, A. Chavez-Blanco, E. Angeles, G. Cabrera, K. Sandoval, C. Trejo-Becerril, J. Chanona-Vilchis, and A. Duenas-Gonzalez A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes BMC Cancer 5 2005 44
35. B. Brueckner, R. Garcia Boy, P. Siedlecki, T. Musch, H.C. Kliem, P. Zielenkiewicz, S. Suhai, M. Wiessler, and F. Lyko Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases Cancer Res. 65 2005 6305 6311
36. J. Datta, K. Ghoshal, W.A. Denny, S.A. Gamage, D.G. Brooke, P. Phiasivongsa, S. Redkar, and S.T. Jacob A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation Cancer Res. 69 2009 4277 4285
37. E. Winquist, J. Knox, J.P. Ayoub, L. Wood, N. Wainman, G.K. Reid, L. Pearce, A. Shah, and E. Eisenhauer Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study Investig. New Drugs 24 2006 159 167
38. R.B. Klisovic, W. Stock, S. Cataland, M.I. Klisovic, S. Liu, W. Blum, M. Green, O. Odenike, L. Godley, J.V. Burgt, E. Van Laar, M. Cullen, A.R. Macleod, J.M. Besterman, G.K. Reid, J.C. Byrd, and G. Marcucci A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia Clin. Cancer Res. 14 2008 2444 2449
39. R. Plummer, L. Vidal, M. Griffin, M. Lesley, J. de Bono, S. Coulthard, J. Sludden, L.L. Siu, E.X. Chen, A.M. Oza, G.K. Reid, A.R. McLeod, J.M. Besterman, C. Lee, I. Judson, H. Calvert, and A.V. Boddy Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors Clin. Cancer Res. 15 2009 3177 3183
40. A.B. Kornblith, J.E. Herndon 2nd, L.R. Silverman, E.P. Demakos, R. Odchimar-Reissig, J.F. Holland, B.L. Powell, C. DeCastro, J. Ellerton, R.A. Larson, C.A. Schiffer, and J.C. Holland Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study J. Clin. Oncol. 20 2002 2441 2452
41. H. Kantarjian, J.P. Issa, C.S. Rosenfeld, J.M. Bennett, M. Albitar, J. DiPersio, V. Klimek, J. Slack, C. de Castro, F. Ravandi, R. Helmer 3rd, L. Shen, S.D. Nimer, R. Leavitt, A. Raza, and H. Saba Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
42. L.R. Silverman, D.R. McKenzie, B.L. Peterson, J.F. Holland, J.T. Backstrom, C.L. Beach, and R.A. Larson Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J. Clin. Oncol. 24 2006 3895 3903
43. L.R. Silverman, E.P. Demakos, B.L. Peterson, A.B. Kornblith, J.C. Holland, R. Odchimar-Reissig, R.M. Stone, D. Nelson, B.L. Powell, C.M. DeCastro, J. Ellerton, R.A. Larson, C.A. Schiffer, and J.F. Holland Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J. Clin. Oncol. 20 2002 2429 2440
44. J.H. Lee, K.H. Lee, D.Y. Kim, S.H. Kim, S.N. Lim, S.D. Kim, Y. Choi, S.M. Lee, W.S. Lee, M.Y. Choi, and Y.D. Joo Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome Leuk. Res. 35 2011 499 503
45. T. Qin, R. Castoro, S. El Ahdab, J. Jelinek, X. Wang, J. Si, J. Shu, R. He, N. Zhang, W. Chung, H.M. Kantarjian, and J.P. Issa Mechanisms of resistance to decitabine in the myelodysplastic syndrome PLoS One 6 2011 e23372
46. J.F. Seymour, P. Fenaux, L.R. Silverman, G.J. Mufti, E. Hellstrom-Lindberg, V. Santini, A.F. List, S.D. Gore, J. Backstrom, D. McKenzie, and C.L. Beach Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes Crit. Rev. Oncol. Hematol. 76 2010 218 227
47. M. Lubbert, S. Suciu, L. Baila, B.H. Ruter, U. Platzbecker, A. Giagounidis, D. Selleslag, B. Labar, U. Germing, H.R. Salih, F. Beeldens, P. Muus, K.H. Pfluger, C. Coens, A. Hagemeijer, H. Eckart Schaefer, A. Ganser, C. Aul, T. de Witte, and P.W. Wijermans Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J. Clin. Oncol. 29 2011 1987 1996
48. M. Lubbert, B. Ruter, R. Claus, C. Schmoor, M. Schmid, U. Germing, A. Kundgen, V. Rethwisch, A. Ganser, U. Platzbecker, O. Galm, W. Brugger, G. Heil, B. Hackanson, B. Deschler, K. Dohner, A. Hagemeijer, P. Wijermans, and H. Dohner A multicenter phase II trial of Decitabine as first-line treatment of older AML patients judged unfit for induction chemotherapy Haematologica 2011
49. T. Braun, R. Itzykson, A. Renneville, B. de Renzis, F. Dreyfus, K. Laribi, K. Bouabdallah, N. Vey, A. Toma, C. Recher, B. Royer, B. Joly, A. Vekhoff, I. Lafon, L. Sanhes, G. Meurice, C. Orear, C. Preudhomme, C. Gardin, L. Ades, M. Fontenay, P. Fenaux, N. Droin, and E. Solary Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial Blood 118 2011 3824 3831
50. P. Fenaux, G.J. Mufti, E. Hellstrom-Lindberg, V. Santini, C. Finelli, A. Giagounidis, R. Schoch, N. Gattermann, G. Sanz, A. List, S.D. Gore, J.F. Seymour, J.M. Bennett, J. Byrd, J. Backstrom, L. Zimmerman, D. McKenzie, C. Beach, and L.R. Silverman Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol. 10 2009 223 232
51. R.M. Lyons, T.M. Cosgriff, S.S. Modi, R.H. Gersh, J.D. Hainsworth, A.L. Cohn, H.J. McIntyre, I.J. Fernando, J.T. Backstrom, and C.L. Beach Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes J. Clin. Oncol. 27 2009 1850 1856
52. M.G. Martin, R.A. Walgren, E. Procknow, G.L. Uy, K. Stockerl-Goldstein, A.F. Cashen, P. Westervelt, C.N. Abboud, F. Kreisel, K. Augustin, J.F. Dipersio, and R. Vij A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes Am. J. Hematol. 84 2009 560 564
53. G. Garcia-Manero, S.D. Gore, C. Cogle, R. Ward, T. Shi, K.J. Macbeth, E. Laille, H. Giordano, S. Sakoian, E. Jabbour, H. Kantarjian, and B. Skikne Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia J. Clin. Oncol. 29 2011 2521 2527
54. D.P. Steensma, M.R. Baer, J.L. Slack, R. Buckstein, L.A. Godley, G. Garcia-Manero, M. Albitar, J.S. Larsen, S. Arora, M.T. Cullen, and H. Kantarjian Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial J. Clin. Oncol. 27 2009 3842 3848
55. H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O'Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, A. Ferrajoli, W. Wierda, J. Shan, J. Davis, F. Giles, H.I. Saba, and J.P. Issa Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 2007 52 57
56. C. Stresemann, I. Bokelmann, U. Mahlknecht, and F. Lyko Azacytidine causes complex DNA methylation responses in myeloid leukemia Mol. Cancer Ther. 7 2008 2998 3005
57. D.J. Stewart, J.P. Issa, R. Kurzrock, M.I. Nunez, J. Jelinek, D. Hong, Y. Oki, Z. Guo, S. Gupta, and Wistuba II Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas Clin. Cancer Res. 15 2009 3881 3888
58. A. Stathis, S.J. Hotte, E.X. Chen, H.W. Hirte, A.M. Oza, P. Moretto, S. Webster, A. Laughlin, L.A. Stayner, S. McGill, L. Wang, W.J. Zhang, I. Espinoza-Delgado, J.L. Holleran, M.J. Egorin, and L.L. Siu Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas Clin. Cancer Res. 17 2011 1582 1590
59. V. Pappa, K. Girkas, C. Sambani, S. Pagageorgiou, P. Tsirigiotis, K. Karvounis, E. Stathopoulou, T. Economopoulos, G. Dimitriadis, and I. Dervenoulas Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: outcomes of prolonged therapy Leuk. Res. 36 2012 e78 e80
60. C. Flotho, R. Claus, C. Batz, M. Schneider, I. Sandrock, S. Ihde, C. Plass, C.M. Niemeyer, and M. Lubbert The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells Leukemia 23 2009 1019 1028
61. P.W. Hollenbach, A.N. Nguyen, H. Brady, M. Williams, Y. Ning, N. Richard, L. Krushel, S.L. Aukerman, C. Heise, and K.J. MacBeth A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines PLoS One 5 2010 e9001
62. G. Borthakur, S.E. Ahdab, F. Ravandi, S. Faderl, A. Ferrajoli, B. Newman, J.P. Issa, and H. Kantarjian Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine Leuk. Lymphoma 49 2008 690 695
63. T. Prebet, S.D. Gore, B. Esterni, C. Gardin, R. Itzykson, S. Thepot, F. Dreyfus, O.B. Rauzy, C. Recher, L. Ades, B. Quesnel, C.L. Beach, P. Fenaux, and N. Vey Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure J. Clin. Oncol. 29 2011 3322 3327
64. T. Prebet, S.D. Gore, S. Thepot, B. Esterni, B. Quesnel, O.B. Rauzy, F. Dreyfus, C. Gardin, P. Fenaux, and N. Vey Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure Br. J. Haematol. 2012
65. E. Jabbour, G. Garcia-Manero, N. Batty, J. Shan, S. O'Brien, J. Cortes, F. Ravandi, J.P. Issa, and H. Kantarjian Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy Cancer 116 2010 3830 3834
66. T.M. Kadia, E. Jabbour, and H. Kantarjian Failure of hypomethylating agent-based therapy in myelodysplastic syndromes Semin. Oncol. 38 2011 682 692
67. F. Folmer, B. Orlikova, M. Schnekenburger, M. Dicato, and M. Diederich Naturally occurring regulators of histone acetylation/deacetylation Curr. Nutr. Food Sci. 6 2010 78 99
68. H. Ozdag, A.E. Teschendorff, A.A. Ahmed, S.J. Hyland, C. Blenkiron, L. Bobrow, A. Veerakumarasivam, G. Burtt, T. Subkhankulova, M.J. Arends, V.P. Collins, D. Bowtell, T. Kouzarides, J.D. Brenton, and C. Caldas Differential expression of selected histone modifier genes in human solid cancers BMC Genomics 7 2006 90
69. C.A. Bradbury, F.L. Khanim, R. Hayden, C.M. Bunce, D.A. White, M.T. Drayson, C. Craddock, and B.M. Turner Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors Leukemia 19 2005 1751 1759
70. D. Khabele, D.S. Son, A.K. Parl, G.L. Goldberg, L.H. Augenlicht, J.M. Mariadason, and V.M. Rice Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy Cancer Biol. Ther. 6 2007 795 801
71. A. Clocchiatti, C. Florean, and C. Brancolini Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis J. Cell. Mol. Med. 15 2011 1833 1846
72. P.A. Marks, and R. Breslow Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 25 2007 84 90
73. C. Seidel, M. Schnekenburger, M. Dicato, M. Diederich, Histone deacetylase modulators provided by Mother Nature, Genes and Nutrition (In press).
74. C. Monneret Histone deacetylase inhibitors Eur. J. Med. Chem. 40 2005 1 13
75. A.V. Bieliauskas, and M.K. Pflum Isoform-selective histone deacetylase inhibitors Chem. Soc. Rev. 37 2008 1402 1413
76. T. Kumagai, N. Wakimoto, D. Yin, S. Gery, N. Kawamata, N. Takai, N. Komatsu, A. Chumakov, Y. Imai, and H.P. Koeffler Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells J. International Du Cancer Int. J. Cancer 121 2007 656 665
77. Y.B. Kim, K.H. Lee, K. Sugita, M. Yoshida, and S. Horinouchi Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase Oncogene 18 1999 2461 2470
78. S. Liu, H. Cheng, W. Kwan, J.M. Lubieniecka, and T.O. Nielsen Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models Mol. Cancer Ther. 7 2008 1751 1761
79. A. Petrella, C.W. D'Acunto, M. Rodriquez, M. Festa, A. Tosco, I. Bruno, S. Terracciano, M. Taddei, L.G. Paloma, and L. Parente Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1 Eur. J. Cancer 44 2008 740 749
80. S. Chateauvieux, S. Eifes, F. Morceau, C. Grigorakaki, M. Schnekenburger, E. Henry, M. Dicato, and M. Diederich Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway Biochem. Pharmacol. 81 2011 498 509
81. M. Schnekenburger, F. Morceau, E. Henry, R. Blasius, M. Dicato, C. Trentesaux, and M. Diederich Transcriptional and post-transcriptional regulation of glutathione S-transferase P1 expression during butyric acid-induced differentiation of K562 cells Leuk. Res. 30 2006 561 568
82. K.A. Blum, A. Advani, L. Fernandez, R. Van Der Jagt, J. Brandwein, S. Kambhampati, J. Kassis, M. Davis, C. Bonfils, M. Dubay, J. Dumouchel, M. Drouin, D.M. Lucas, R.E. Martell, and J.C. Byrd Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia Br. J. Haematol. 147 2009 507 514
83. A. Hauschild, U. Trefzer, C. Garbe, K.C. Kaehler, S. Ugurel, F. Kiecker, T. Eigentler, H. Krissel, A. Schott, and D. Schadendorf Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)- carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma Melanoma Res. 18 2008 274 278
84. R.L. Piekarz, R. Frye, M. Turner, J.J. Wright, S.L. Allen, M.H. Kirschbaum, J. Zain, H.M. Prince, J.P. Leonard, L.J. Geskin, C. Reeder, D. Joske, W.D. Figg, E.R. Gardner, S.M. Steinberg, E.S. Jaffe, M. Stetler-Stevenson, S. Lade, A.T. Fojo, and S.E. Bates Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J. Clin. Oncol. 27 2009 5410 5417
85. S.J. Whittaker, M.F. Demierre, E.J. Kim, A.H. Rook, A. Lerner, M. Duvic, J. Scarisbrick, S. Reddy, T. Robak, J.C. Becker, A. Samtsov, W. McCulloch, and Y.H. Kim Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma J. Clin. Oncol. 28 2010 4485 4491
86. M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J.H. Chiao, J.F. Reilly, J.L. Ricker, V.M. Richon, and S.R. Frankel Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 2007 31 39
87. T.H. Luu, R.J. Morgan, L. Leong, D. Lim, M. McNamara, J. Portnow, P. Frankel, D.D. Smith, J.H. Doroshow, C. Wong, A. Aparicio, D.R. Gandara, and G. Somlo A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study Clin. Cancer Res. 14 2008 7138 7142
88. A.M. Traynor, S. Dubey, J.C. Eickhoff, J.M. Kolesar, K. Schell, M.S. Huie, D.L. Groteluschen, S.M. Marcotte, C.M. Hallahan, H.R. Weeks, G. Wilding, I. Espinoza-Delgado, and J.H. Schiller Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study J. Thoracic Oncol.: Official Publication Int. Assoc. Study Lung Cancer 4 2009 522 526
89. S.C. Modesitt, M. Sill, J.S. Hoffman, and D.P. Bender A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 109 2008 182 186
90. J.A. Woyach, R.T. Kloos, M.D. Ringel, D. Arbogast, M. Collamore, J.A. Zwiebel, M. Grever, M. Villalona-Calero, and M.H. Shah Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma J. Clin. Endocrinol. Metab. 94 2009 164 170
91. A. Rambaldi, C.M. Dellacasa, G. Finazzi, A. Carobbio, M.L. Ferrari, P. Guglielmelli, E. Gattoni, S. Salmoiraghi, M.C. Finazzi, S. Di Tollo, C. D'Urzo, A.M. Vannucchi, G. Barosi, and T. Barbui A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms Br. J. Haematol. 150 2010 446 455
92. M. Galli, S. Salmoiraghi, J. Golay, A. Gozzini, C. Crippa, N. Pescosta, and A. Rambaldi A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma Ann. Hematology 89 2010 185 190
93. J.S. de Bono, R. Kristeleit, A. Tolcher, P. Fong, S. Pacey, V. Karavasilis, M. Mita, H. Shaw, P. Workman, S. Kaye, E.K. Rowinsky, W. Aherne, P. Atadja, J.W. Scott, and A. Patnaik Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors Clin. Cancer Res. 14 2008 6663 6673
94. L. Ellis, M. Bots, R.K. Lindemann, J.E. Bolden, A. Newbold, L.A. Cluse, C.L. Scott, A. Strasser, P. Atadja, S.W. Lowe, and R.W. Johnstone The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy Blood 114 2009 380 393
95. F. Giles, T. Fischer, J. Cortes, G. Garcia-Manero, J. Beck, F. Ravandi, E. Masson, P. Rae, G. Laird, S. Sharma, H. Kantarjian, M. Dugan, M. Albitar, and K. Bhalla A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clin. Cancer Res. 12 2006 4628 4635
96. S.S. Ramalingam, C.P. Belani, C. Ruel, P. Frankel, B. Gitlitz, M. Koczywas, I. Espinoza-Delgado, and D. Gandara Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma J. Thoracic Oncol.: Official Publication Int. Assoc. Study Lung Cancer 4 2009 97 101
97. A.R. Razak, S.J. Hotte, L.L. Siu, E.X. Chen, H.W. Hirte, J. Powers, W. Walsh, L.A. Stayner, A. Laughlin, V. Novotny-Diermayr, J. Zhu, and E.A. Eisenhauer Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours Br. J. Cancer 104 2011 756 762
98. J.M. Su, X.N. Li, P. Thompson, C.N. Ou, A.M. Ingle, H. Russell, C.C. Lau, P.C. Adamson, and S.M. Blaney Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report Clin. Cancer Res. 17 2011 589 597
99. O.M. Rahal, and R.C. Simmen PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation Carcinogenesis 31 2010 1491 1500
100. N. Gao, S. Cheng, A. Budhraja, E.H. Liu, J. Chen, D. Chen, Z. Yang, J. Luo, X. Shi, and Z. Zhang 3,3'-Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Akt-dependent process PLoS One 7 2012 e31783
101. N. Gao, A. Budhraja, S. Cheng, E.H. Liu, J. Chen, Z. Yang, D. Chen, Z. Zhang, and X. Shi Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways Cell Death Dis. 2 2011 e140
102. D. Xiao, A.A. Powolny, M.B. Moura, E.E. Kelley, A. Bommareddy, S.H. Kim, E.R. Hahm, D. Normolle, B. Van Houten, and S.V. Singh Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells J. Biol. Chem. 285 2010 26558 26569
103. C.J. Lai, R. Bao, X. Tao, J. Wang, R. Atoyan, H. Qu, D.G. Wang, L. Yin, M. Samson, J. Forrester, B. Zifcak, G.X. Xu, S. DellaRocca, H.X. Zhai, X. Cai, W.E. Munger, M. Keegan, C.V. Pepicelli, and C. Qian CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity Cancer Res. 70 2010 3647 3656
104. M. Namdar, G. Perez, L. Ngo, and P.A. Marks Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents Proc. Natl. Acad. Sci. U.S.A. 107 2010 20003 20008
105. S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, and J.J. Buggy A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Leukemia 22 2008 1026 1034
106. T.M. Kadia, H. Yang, A. Ferrajoli, S. Maddipotti, C. Schroeder, T.L. Madden, J.L. Holleran, M.J. Egorin, F. Ravandi, D.A. Thomas, W. Newsome, B. Sanchez-Gonzalez, J.A. Zwiebel, I. Espinoza-Delgado, H.M. Kantarjian, and G. Garcia-Manero A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia Br. J. Haematol. 150 2010 72 82
107. C.P. Miller, M.M. Singh, N. Rivera-Del Valle, C.A. Manton, and J. Chandra Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors J. Biomed. Biotechnol. 2011 2011 514261
108. T. Vaissiere, C. Sawan, and Z. Herceg Epigenetic interplay between histone modifications and DNA methylation in gene silencing Mutat. Res. 659 2008 40 48
109. R.L. Momparler Cancer epigenetics Oncogene 22 2003 6479 6483
110. S. Stintzing, R. Kemmerling, T. Kiesslich, B. Alinger, M. Ocker, and D. Neureiter Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J. Biomed. Biotechnol. 2011 2011 214143
111. T.E. Fandy, J.G. Herman, P. Kerns, A. Jiemjit, E.A. Sugar, S.H. Choi, A.S. Yang, T. Aucott, T. Dauses, R. Odchimar-Reissig, J. Licht, M.J. McConnell, C. Nasrallah, M.K. Kim, W. Zhang, Y. Sun, A. Murgo, I. Espinoza-Delgado, K. Oteiza, I. Owoeye, L.R. Silverman, S.D. Gore, and H.E. Carraway Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Blood 114 2009 2764 2773
112. P. Maslak, S. Chanel, L.H. Camacho, S. Soignet, P.P. Pandolfi, I. Guernah, R. Warrell, and S. Nimer Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome Leukemia 20 2006 212 217
113. F. Braiteh, A.O. Soriano, G. Garcia-Manero, D. Hong, M.M. Johnson, P. Silva Lde, H. Yang, S. Alexander, J. Wolff, and R. Kurzrock Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers Clin. Cancer Res. 14 2008 6296 6301
114. E. Raffoux, A. Cras, C. Recher, P.Y. Boelle, A. de Labarthe, P. Turlure, J.P. Marolleau, O. Reman, C. Gardin, M. Victor, S. Maury, P. Rousselot, J.V. Malfuson, O. Maarek, M.T. Daniel, P. Fenaux, L. Degos, C. Chomienne, S. Chevret, and H. Dombret Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome Oncotarget 1 2010 34 42
115. A.O. Soriano, H. Yang, S. Faderl, Z. Estrov, F. Giles, F. Ravandi, J. Cortes, W.G. Wierda, S. Ouzounian, A. Quezada, S. Pierce, E.H. Estey, J.P. Issa, H.M. Kantarjian, and G. Garcia-Manero Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 110 2007 2302 2308
116. G. Garcia-Manero, H.M. Kantarjian, B. Sanchez-Gonzalez, H. Yang, G. Rosner, S. Verstovsek, M. Rytting, W.G. Wierda, F. Ravandi, C. Koller, L. Xiao, S. Faderl, Z. Estrov, J. Cortes, S. O'Brien, E. Estey, C. Bueso-Ramos, J. Fiorentino, E. Jabbour, and J.P. Issa Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia Blood 108 2006 3271 3279
117. K.A. Blum, Z. Liu, D.M. Lucas, P. Chen, Z. Xie, R. Baiocchi, D.M. Benson, S.M. Devine, J. Jones, L. Andritsos, J. Flynn, C. Plass, G. Marcucci, K.K. Chan, M.R. Grever, and J.C. Byrd Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation Br. J. Haematol. 150 2010 189 195
118. T.J. Ley, L. Ding, M.J. Walter, M.D. McLellan, T. Lamprecht, D.E. Larson, C. Kandoth, J.E. Payton, J. Baty, J. Welch, C.C. Harris, C.F. Lichti, R.R. Townsend, R.S. Fulton, D.J. Dooling, D.C. Koboldt, H. Schmidt, Q. Zhang, J.R.
119. G.A. Challen, D. Sun, M. Jeong, M. Luo, J. Jelinek, J.S. Berg, C. Bock, A. Vasanthakumar, H. Gu, Y. Xi, S. Liang, Y. Lu, G.J. Darlington, A. Meissner, J.P. Issa, L.A. Godley, W. Li, and M.A. Goodell Dnmt3a is essential for hematopoietic stem cell differentiation Nat. Genet. 44 2012 23 31
120. K.H. Metzeler, A. Walker, S. Geyer, R. Garzon, R.B. Klisovic, C.D. Bloomfield, W. Blum, and G. Marcucci DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia Leukemia 2011
121. R. Garzon, S. Liu, M. Fabbri, Z. Liu, C.E. Heaphy, E. Callegari, S. Schwind, J. Pang, J. Yu, N. Muthusamy, V. Havelange, S. Volinia, W. Blum, L.J. Rush, D. Perrotti, M. Andreeff, C.D. Bloomfield, J.C. Byrd, K. Chan, L.C. Wu, C.M. Croce, and G. Marcucci MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 Blood 113 2009 6411 6418
122. W. Blum, R. Garzon, R.B. Klisovic, S. Schwind, A. Walker, S. Geyer, S. Liu, V. Havelange, H. Becker, L. Schaaf, J. Mickle, H. Devine, C. Kefauver, S.M. Devine, K.K. Chan, N.A. Heerema, C.D. Bloomfield, M.R. Grever, J.C. Byrd, M. Villalona-Calero, C.M. Croce, and G. Marcucci Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine Proc. Natl. Acad. Sci. U.S.A. 107 2010 7473 7478
123. H.A. Hou, Y.Y. Kuo, C.Y. Liu, W.C. Chou, M.C. Lee, C.Y. Chen, L.I. Lin, M.H. Tseng, C.F. Huang, Y.C. Chiang, F.Y. Lee, M.C. Liu, C.W. Liu, J.L. Tang, M. Yao, S.Y. Huang, B.S. Ko, S.C. Hsu, S.J. Wu, W. Tsay, Y.C. Chen, and H.F. Tien DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications Blood 119 2012 559 568
124. M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, F. Ducray, S. El Hallani, B. Boisselier, K. Mokhtari, K. Hoang-Xuan, and J.Y. Delattre Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J. Clin. Oncol. 27 2009 4150 4154
125. C. Lu, P.S. Ward, G.S. Kapoor, D. Rohle, S. Turcan, O. Abdel-Wahab, C.R. Edwards, R. Khanin, M.E. Figueroa, A. Melnick, K.E. Wellen, D.M. O'Rourke, S.L. Berger, T.A. Chan, R.L. Levine, I.K. Mellinghoff, and C.B. Thompson IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 483 2012 474 478
126. M.E. Figueroa, O. Abdel-Wahab, C. Lu, P.S. Ward, J. Patel, A. Shih, Y. Li, N. Bhagwat, A. Vasanthakumar, H.F. Fernandez, M.S. Tallman, Z. Sun, K. Wolniak, J.K. Peeters, W. Liu, S.E. Choe, V.R. Fantin, E. Paietta, B. Lowenberg, J.D. Licht, L.A. Godley, R. Delwel, P.J. Valk, C.B. Thompson, R.L. Levine, and A. Melnick Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 2010 553 567
127. S. Turcan, D. Rohle, A. Goenka, L.A. Walsh, F. Fang, E. Yilmaz, C. Campos, A.W. Fabius, C. Lu, P.S. Ward, C.B. Thompson, A. Kaufman, O. Guryanova, R. Levine, A. Heguy, A. Viale, L.G. Morris, J.T. Huse, I.K. Mellinghoff, and T.A. Chan IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 2012 479 483
128. K. Williams, J. Christensen, and K. Helin DNA methylation: TET proteins-guardians of CpG islands? EMBO Reports 13 2011 28 35
129. N. Carey, C.J. Marques, and W. Reik DNA demethylases: a new epigenetic frontier in drug discovery Drug Discovery Today 16 2011 683 690
130. O. Kosmider, V. Gelsi-Boyer, M. Cheok, S. Grabar, V. Della-Valle, F. Picard, F. Viguie, B. Quesnel, O. Beyne-Rauzy, E. Solary, N. Vey, M. Hunault-Berger, P. Fenaux, V. Mansat-De Mas, E. Delabesse, P. Guardiola, C. Lacombe, W. Vainchenker, C. Preudhomme, F. Dreyfus, O.A. Bernard, D. Birnbaum, and M. Fontenay TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood 114 2009 3285 3291
131. A.E. Smith, A.M. Mohamedali, A. Kulasekararaj, Z. Lim, J. Gaken, N.C. Lea, B. Przychodzen, S.A. Mian, E.E. Nasser, C. Shooter, N.B. Westwood, C. Strupp, N. Gattermann, J.P. Maciejewski, U. Germing, and G.J. Mufti Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value Blood 116 2010 3923 3932
132. O. Nibourel, O. Kosmider, M. Cheok, N. Boissel, A. Renneville, N. Philippe, H. Dombret, F. Dreyfus, B. Quesnel, S. Geffroy, S. Quentin, C. Roche-Lestienne, J.M. Cayuela, C. Roumier, P. Fenaux, W. Vainchenker, O.A. Bernard, J. Soulier, M. Fontenay, and C. Preudhomme Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission Blood 116 2010 1132 1135
133. V.I. Gaidzik, P. Paschka, D. Spath, M. Habdank, C.H. Kohne, U. Germing, M. von Lilienfeld-Toal, G. Held, H.A. Horst, D. Haase, M. Bentz, K. Gotze, H. Dohner, R.F. Schlenk, L. Bullinger, and K. Dohner TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML Study Group J. Clin. Oncol. 2012
134. M.T. Voso, E. Fabiani, A. Piciocchi, C. Matteucci, L. Brandimarte, C. Finelli, E. Pogliani, E. Angelucci, G. Fioritoni, P. Musto, M. Greco, M. Criscuolo, L. Fianchi, M. Vignetti, V. Santini, S. Hohaus, C. Mecucci, and G. Leone Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine Leukemia 25 2011 1910 1913
135. R. Itzykson, O. Kosmider, T. Cluzeau, V. Mansat-De Mas, F. Dreyfus, O. Beyne-Rauzy, B. Quesnel, N. Vey, V. Gelsi-Boyer, S. Raynaud, C. Preudhomme, L. Ades, P. Fenaux, and M. Fontenay Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Leukemia 25 2011 1147 1152
136. S. Ropero, M.F. Fraga, E. Ballestar, R. Hamelin, H. Yamamoto, M. Boix-Chornet, R. Caballero, M. Alaminos, F. Setien, M.F. Paz, M. Herranz, J. Palacios, D. Arango, T.F. Orntoft, L.A. Aaltonen, S. Schwartz Jr., and M. Esteller A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition Nat. Genet. 38 2006 566 569
137. J.M. Mariadason Making sense of HDAC2 mutations in colon cancer Gastroenterology 135 2008 1457 1459
138. T. Sjoblom, S. Jones, L.D. Wood, D.W. Parsons, J. Lin, T.D. Barber, D. Mandelker, R.J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S.D. Markowitz, J. Willis, D. Dawson, J.K. Willson, A.F. Gazdar, J. Hartigan, L. Wu, C. Liu, G. Parmigiani, B.H. Park, K.E. Bachman, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, and V.E. Velculescu The consensus coding sequences of human breast and colorectal cancers Science 314 2006 268 274
139. A. Lakshmikuttyamma, S.A. Scott, J.F. DeCoteau, and C.R. Geyer Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition Oncogene 29 2010 576 588
140. W. Fiskus, Y. Wang, A. Sreekumar, K.M. Buckley, H. Shi, A. Jillella, C. Ustun, R. Rao, P. Fernandez, J. Chen, R. Balusu, S. Koul, P. Atadja, V.E. Marquez, and K.N. Bhalla Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells Blood 114 2009 2733 2743
141. S. Vernarecci, F. Tosi, and P. Filetici Tuning acetylated chromatin with HAT inhibitors: a novel tool for therapy Epigenetics 5 2010 105 111
142. F.H. Kwie, M. Briet, D. Soupaya, P. Hoffmann, M. Maturano, F. Rodriguez, C. Blonski, C. Lherbet, and C. Baudoin-Dehoux New potent bisubstrate inhibitors of histone acetyltransferase p300: design, synthesis and biological evaluation Chem. Biol. Drug Des. 77 2011 86 92
143. S.R. Daigle, E.J. Olhava, C.A. Therkelsen, C.R. Majer, C.J. Sneeringer, J. Song, L.D. Johnston, M.P. Scott, J.J. Smith, Y. Xiao, L. Jin, K.W. Kuntz, R. Chesworth, M.P. Moyer, K.M. Bernt, J.C. Tseng, A.L. Kung, S.A. Armstrong, R.A. Copeland, V.M. Richon, and R.M. Pollock Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor Cancer Cell 20 2011 53 65
144. Y. Yao, P. Chen, J. Diao, G. Cheng, L. Deng, J.L. Anglin, B.V. Prasad, and Y. Song Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies J. Am. Chem. Soc. 133 2011 16746 16749
145. J. Zhou, C. Bi, L.L. Cheong, S. Mahara, S.C. Liu, K.G. Tay, T.L. Koh, Q. Yu, and W.J. Chng The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML Blood 118 2011 2830 2839
146. T. Schenk, W.C. Chen, S. Gollner, L. Howell, L. Jin, K. Hebestreit, H.U. Klein, A.C. Popescu, A. Burnett, K. Mills, R.A. Casero Jr., L. Marton, P. Woster, M.D. Minden, M. Dugas, J.C. Wang, J.E. Dick, C. Muller-Tidow, K. Petrie, and A. Zelent Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia Nat. Med. 2012
147. N. Bhatnagar, X. Li, Y. Chen, X. Zhou, S.H. Garrett, and B. Guo 3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin Cancer Prevention Res. 2 2009 581 589
148. A.N. Khan, W.J. Magner, and T.B. Tomasi An epigenetic vaccine model active in the prevention and treatment of melanoma J. Transl. Med. 5 2007 64
149. J.M. Foulks, K.M. Parnell, R.N. Nix, S. Chau, K. Swierczek, M. Saunders, K. Wright, T.F. Hendrickson, K.K. Ho, M.V. McCullar, and S.B. Kanner Epigenetic drug discovery: targeting DNA methyltransferases J. Biomol. Screen. 17 2012 2 17
150. A. Link, F. Balaguer, and A. Goel Cancer chemoprevention by dietary polyphenols: promising role for epigenetics Biochem. Pharmacol. 80 2010 1771 1792
151. Z. Liu, Z. Xie, W. Jones, R.E. Pavlovicz, S. Liu, J. Yu, P.K. Li, J. Lin, J.R. Fuchs, G. Marcucci, C. Li, and K.K. Chan Curcumin is a potent DNA hypomethylation agent Bioorg. Med. Chem. Lett. 19 2009 706 709
152. M. Adjakly, R. Bosviel, N. Rabiau, J.P. Boiteux, Y.J. Bignon, L. Guy, and D. Bernard-Gallon DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines Epigenomics 3 2011 795 803
153. S. Jagadeesh, S. Sinha, B.C. Pal, S. Bhattacharya, and P.P. Banerjee Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells Biochem. Biophys. Res. Commun. 362 2007 212 217
154. D. Kuck, T. Caulfield, F. Lyko, and J.L. Medina-Franco Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells Mol. Cancer Ther. 9 2010 3015 3023
155. I.C. Pina, J.T. Gautschi, G.Y. Wang, M.L. Sanders, F.J. Schmitz, D. France, S. Cornell-Kennon, L.C. Sambucetti, S.W. Remiszewski, L.B. Perez, K.W. Bair, and P. Crews Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase J. Org. Chem. 68 2003 3866 3873
156. J. Lin, M.C. Haffner, Y. Zhang, B.H. Lee, W.N. Brennen, J. Britton, S.K. Kachhap, J.S. Shim, J.O. Liu, W.G. Nelson, S. Yegnasubramanian, and M.A. Carducci Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth The Prostate 71 2011 333 343
157. J. Coronel, L. Cetina, I. Pacheco, C. Trejo-Becerril, A. Gonzalez-Fierro, E. de la Cruz-Hernandez, E. Perez-Cardenas, L. Taja-Chayeb, D. Arias-Bofill, M. Candelaria, S. Vidal, and A. Duenas-Gonzalez A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results Med. Oncol. 28 Suppl. 1 2011 540 546
158. M. Candelaria, A. Herrera, J. Labardini, A. Gonzalez-Fierro, C. Trejo-Becerril, L. Taja-Chayeb, E. Perez-Cardenas, E. de la Cruz-Hernandez, D. Arias-Bofill, S. Vidal, E. Cervera, and A. Duenas-Gonzalez Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial Ann. Hematol. 90 2011 379 387
159. B.H. Lee, S. Yegnasubramanian, X. Lin, and W.G. Nelson Procainamide is a specific inhibitor of DNA methyltransferase 1 J. Biol. Chem. 280 2005 40749 40756
160. Z.Q. Ning, Z.B. Li, M.J. Newman, S. Shan, X.H. Wang, D.S. Pan, J. Zhang, M. Dong, X. Du, and X.P. Lu Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity Cancer Chemotherapy Pharmacol. 2011
161. A.J. Kraker, C.A. Mizzen, B.G. Hartl, J. Miin, C.D. Allis, and R.L. Merriman Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino- phenyl) benzamide] in HCT-8 colon carcinoma Mol. Cancer Ther. 2 2003 401 408
162. N. Takai, T. Ueda, M. Nishida, K. Nasu, and H. Narahara M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells Gynecol. Oncol. 101 2006 108 113
163. M. Fournel, C. Bonfils, Y. Hou, P.T. Yan, M.C. Trachy-Bourget, A. Kalita, J. Liu, A.H. Lu, N.Z. Zhou, M.F. Robert, J. Gillespie, J.J. Wang, H. Ste-Croix, J. Rahil, S. Lefebvre, O. Moradei, D. Delorme, A.R. Macleod, J.M. Besterman, and Z. Li MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Ther. 7 2008 759 768
164. A. Saito, T. Yamashita, Y. Mariko, Y. Nosaka, K. Tsuchiya, T. Ando, T. Suzuki, T. Tsuruo, and O. Nakanishi A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors Proc. Natl. Acad. Sci. U.S.A. 96 1999 4592 4597
165. S. Varghese, T. Senanayake, T. Murray-Stewart, K. Doering, A. Fraser, R.A. Casero Jr., and P.M. Woster Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors J. Med. Chem. 51 2008 2447 2456
166. J.W. Han, S.H. Ahn, S.H. Park, S.Y. Wang, G.U. Bae, D.W. Seo, H.K. Kwon, S. Hong, H.Y. Lee, Y.W. Lee, and H.W. Lee Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin Cancer Res. 60 2000 6068 6074
167. N. Maulucci, M.G. Chini, S.D. Micco, I. Izzo, E. Cafaro, A. Russo, P. Gallinari, C. Paolini, M.C. Nardi, A. Casapullo, R. Riccio, G. Bifulco, and F.D. Riccardis Molecular insights into azumamide e histone deacetylases inhibitory activity J. Am. Chem. Soc. 129 2007 3007 3012
168. S. De Schepper, H. Bruwiere, T. Verhulst, U. Steller, L. Andries, W. Wouters, M. Janicot, J. Arts, and J. Van Heusden Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin J. Pharmacol. Exp. Ther. 304 2003 881 888
169. G. Brosch, R. Ransom, T. Lechner, J.D. Walton, and P. Loidl Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum The Plant Cell 7 1995 1941 1950
170. R. Furumai, Y. Komatsu, N. Nishino, S. Khochbin, M. Yoshida, and S. Horinouchi Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin Proc. Natl. Acad. Sci. U.S.A. 98 2001 87 92
171. K. Umehara, K. Nakahara, S. Kiyoto, M. Iwami, M. Okamoto, H. Tanaka, M. Kohsaka, H. Aoki, and H. Imanaka Studies on WF-3161, a new antitumor antibiotic J. Antibiotics 36 1983 478 483
172. R. Furumai, A. Matsuyama, N. Kobashi, K.H. Lee, M. Nishiyama, H. Nakajima, A. Tanaka, Y. Komatsu, N. Nishino, M. Yoshida, and S. Horinouchi FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res. 62 2002 4916 4921
173. Y. Ying, K. Taori, H. Kim, J. Hong, and H. Luesch Total synthesis and molecular target of largazole, a histone deacetylase inhibitor J. Am. Chem. Soc. 130 2008 8455 8459
174. S.J. Crabb, M. Howell, H. Rogers, M. Ishfaq, A. Yurek-George, K. Carey, B.M. Pickering, P. East, R. Mitter, S. Maeda, P.W. Johnson, P. Townsend, K. Shin-ya, M. Yoshida, A. Ganesan, and G. Packham Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A Biochem. Pharmacol. 76 2008 463 475
175. K.B. Glaser, J. Li, M.E. Aakre, D.W. Morgan, G. Sheppard, K.D. Stewart, J. Pollock, P. Lee, C.Z. O'Connor, S.N. Anderson, D.J. Mussatto, C.W. Wegner, and H.L. Moses Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase Mol. Cancer Ther. 1 2002 759 768
176. L. Qiu, M.J. Kelso, C. Hansen, M.L. West, D.P. Fairlie, and P.G. Parsons Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate Br. J. Cancer 80 1999 1252 1258
177. K.A. Fennell, and M.J. Miller Syntheses of amamistatin fragments and determination of their HDAC and antitumor activity Org. Letters 9 2007 1683 1685
178. V.M. Richon, S. Emiliani, E. Verdin, Y. Webb, R. Breslow, R.A. Rifkind, and P.A. Marks A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proc. Natl. Acad. Sci. U.S.A. 95 1998 3003 3007
179. Y. Komatsu, K.Y. Tomizaki, M. Tsukamoto, T. Kato, N. Nishino, S. Sato, T. Yamori, T. Tsuruo, R. Furumai, M. Yoshida, S. Horinouchi, and H. Hayashi Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity Cancer Res. 61 2001 4459 4466
180. D. Moffat, S. Patel, F. Day, A. Belfield, A. Donald, M. Rowlands, J. Wibawa, D. Brotherton, L. Stimson, V. Clark, J. Owen, L. Bawden, G. Box, E. Bone, P. Mortenson, A. Hardcastle, S. van Meurs, S. Eccles, F. Raynaud, and W. Aherne Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0] hex-3-yl)-N-hydro xypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor J. Med. Chem. 53 2010 8663 8678
181. P. Tessier, D.V. Smil, A. Wahhab, S. Leit, J. Rahil, Z. Li, R. Deziel, and J.M. Besterman Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 19 2009 5684 5688
182. F. Leoni, G. Fossati, E.C. Lewis, J.K. Lee, G. Porro, P. Pagani, D. Modena, M.L. Moras, P. Pozzi, L.L. Reznikov, B. Siegmund, G. Fantuzzi, C.A. Dinarello, and P. Mascagni The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo Mol. Med. 11 2005 1 15
183. W.G. Tong, Y. Wei, W. Stevenson, S.Q. Kuang, Z. Fang, M. Zhang, J. Arts, and G. Garcia-Manero Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor Leuk. Res. 34 2010 221 228
184. M.R. Kang, J.S. Kang, S.B. Han, J.H. Kim, D.M. Kim, K. Lee, C.W. Lee, K.H. Lee, C.H. Lee, G. Han, H.M. Kim, and S.K. Park A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells Biochem. Pharmacol. 78 2009 486 494
185. D.Z. Qian, Y. Kato, S. Shabbeer, Y. Wei, H.M. Verheul, B. Salumbides, T. Sanni, P. Atadja, and R. Pili Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589 Clin. Cancer Res. 12 2006 634 642
186. L. Catley, E. Weisberg, Y.T. Tai, P. Atadja, S. Remiszewski, T. Hideshima, N. Mitsiades, R. Shringarpure, R. LeBlanc, D. Chauhan, N.C. Munshi, R. Schlossman, P. Richardson, J. Griffin, and K.C. Anderson NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 2003 2615 2622
187. J.J. Buggy, Z.A. Cao, K.E. Bass, E. Verner, S. Balasubramanian, L. Liu, B.E. Schultz, P.R. Young, and S.A. Dalrymple CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo Mol. Cancer Ther. 5 2006 1309 1317
188. J.A. Plumb, P.W. Finn, R.J. Williams, M.J. Bandara, M.R. Romero, C.J. Watkins, N.B. La Thangue, and R. Brown Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol. Cancer Ther. 2 2003 721 728
189. L.M. Butler, Y. Webb, D.B. Agus, B. Higgins, T.R. Tolentino, M.C. Kutko, M.P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo, H.I. Scher, R. Breslow, V.M. Richon, R.A. Rifkind, and P.A. Marks Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase Clin. Cancer Res. 7 2001 962 970
190. H. Wang, Z.Y. Lim, Y. Zhou, M. Ng, T. Lu, K. Lee, K. Sangthongpitag, K.C. Goh, X. Wang, X. Wu, H.H. Khng, S.K. Goh, W.C. Ong, Z. Bonday, and E.T. Sun Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: synthesis, SAR, and in vivo antitumor activity Bioorg. Med. Chem. Lett. 20 2010 3314 3321
191. V. Novotny-Diermayr, K. Sangthongpitag, C.Y. Hu, X. Wu, N. Sausgruber, P. Yeo, G. Greicius, S. Pettersson, A.L. Liang, Y.K. Loh, Z. Bonday, K.C. Goh, H. Hentze, S. Hart, H. Wang, K. Ethirajulu, and J.M. Wood SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer Mol. Cancer Ther. 9 2010 642 652
192. E.J. Lee, B.B. Lee, S.J. Kim, Y.D. Park, J. Park, and D.H. Kim Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells Int. J. Oncol. 33 2008 767 776
193. J.H. Park, Y. Jung, T.Y. Kim, S.G. Kim, H.S. Jong, J.W. Lee, D.K. Kim, J.S. Lee, N.K. Kim, and Y.J. Bang Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation Clin. Cancer Res. 10 2004 5271 5281
194. H.J. Woo, S.J. Lee, B.T. Choi, Y.M. Park, and Y.H. Choi Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells Exp. Mol. Pathol. 82 2007 77 84
195. K.V. Butler, J. Kalin, C. Brochier, G. Vistoli, B. Langley, and A.P. Kozikowski Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 132 2010 10842 10846
196. M. Entin-Meer, A. Rephaeli, X. Yang, A. Nudelman, S.R. VandenBerg, and D.A. Haas-Kogan Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas Mol. Cancer Ther. 4 2005 1952 1961
197. S.K. Kulp, C.S. Chen, D.S. Wang, and C.Y. Chen Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer Clin. Cancer Res. 12 2006 5199 5206
198. R.P. Warrell Jr., L.Z. He, V. Richon, E. Calleja, and P.P. Pandolfi Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J. Natl. Cancer Inst. 90 1998 1621 1625
199. J.R. Davie Inhibition of histone deacetylase activity by butyrate J. Nutrition 133 2003 2485S 2493S
200. N. Gurvich, O.M. Tsygankova, J.L. Meinkoth, and P.S. Klein Histone deacetylase is a target of valproic acid-mediated cellular differentiation Cancer Res. 64 2004 1079 1086
201. T.F. Outeiro, E. Kontopoulos, S.M. Altmann, I. Kufareva, K.E. Strathearn, A.M. Amore, C.B. Volk, M.M. Maxwell, J.C. Rochet, P.J. McLean, A.B. Young, R. Abagyan, M.B. Feany, B.T. Hyman, and A.G. Kazantsev Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease Science 317 2007 516 519
202. H. Nian, B. Delage, J.T. Pinto, and R.H. Dashwood Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter Carcinogenesis 29 2008 1816 1824
203. A. Mai, S. Valente, A. Nebbioso, S. Simeoni, R. Ragno, S. Massa, G. Brosch, F. De Bellis, F. Manzo, and L. Altucci New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations Int. J. Biochem. Cell Biol. 41 2009 235 247
204. E.S. Inks, B.J. Josey, S.R. Jesinkey, and C.J. Chou A novel class of small molecule inhibitors of HDAC6 ACS Chemical Biology 2011
205. I.H. Son, S.I. Lee, H.D. Yang, and H.I. Moon Bis(4-hydroxybenzyl)sulfide: a sulfur compound inhibitor of histone deacetylase isolated from root extract of Pleuropterus ciliinervis Molecules 12 2007 815 820
206. J. Savickiene, V.V. Borutinskaite, G. Treigyte, K.E. Magnusson, and R. Navakauskiene The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines Eur. J. Pharmacol. 549 2006 9 18
207. T. Suzuki, A. Kouketsu, A. Matsuura, A. Kohara, S. Ninomiya, K. Kohda, and N. Miyata Thiol-based SAHA analogs as potent histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 14 2004 3313 3317
208. E. Mukwevho, T.A. Kohn, D. Lang, E. Nyatia, J. Smith, and E.O. Ojuka Caffeine induces hyperacetylation of histones at the MEF2 site on the Glut4 promoter and increases MEF2A binding to the site via a CaMK-dependent mechanism Am J Physiol Endocrinol Metab. 294 2008 E582 E588
209. B. Heltweg, T. Gatbonton, A.D. Schuler, J. Posakony, H. Li, S. Goehle, R. Kollipara, R.A. Depinho, Y. Gu, J.A. Simon, and A. Bedalov Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes Cancer Res. 66 2006 4368 4377
210. N. Oku, K. Nagai, N. Shindoh, Y. Terada, R.W. van Soest, S. Matsunaga, and N. Fusetani Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia Bioorg. Med. Chem. Lett. 14 2004 2617 2620
211. N. Druesne, A. Pagniez, C. Mayeur, M. Thomas, C. Cherbuy, P.H. Duee, P. Martel, and C. Chaumontet Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines Carcinogenesis 25 2004 1227 1236
212. H.J. Kwon, T. Owa, C.A. Hassig, J. Shimada, and S.L. Schreiber Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase Proc. Natl. Acad. Sci. U.S.A. 95 1998 3356 3361
213. J.M. Solomon, R. Pasupuleti, L. Xu, T. McDonagh, R. Curtis, P.S. DiStefano, and L.J. Huber Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage Mol. Cell Biol. 26 2006 28 38
214. S. Basak, D. Pookot, E.J. Noonan, and R. Dahiya Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function Mol. Cancer Ther. 7 2008 3195 3202
215. J. Trapp, A. Jochum, R. Meier, L. Saunders, B. Marshall, C. Kunick, E. Verdin, P. Goekjian, W. Sippl, and M. Jung Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition J. Med. Chem. 49 2006 7307 7316
216. S.J. Haggarty, K.M. Koeller, J.C. Wong, R.A. Butcher, and S.L. Schreiber Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays Chem. Biol. 10 2003 383 396
217. P.L. Wash, T.Z. Hoffman, B.M. Wiley, C. Bonnefous, N.D. Smith, M.S. Sertic, C.M. Lawrence, K.T. Symons, P.M. Nguyen, K.D. Lustig, X. Guo, T. Annable, S.A. Noble, J.H. Hager, C.A. Hassig, and J.W. Malecha Alpha-mercaptoketone based histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 18 2008 6482 6485
218. S.D. Xiong, K. Yu, X.H. Liu, L.H. Yin, A. Kirschenbaum, S. Yao, G. Narla, A. DiFeo, J.B. Wu, Y. Yuan, S.M. Ho, Y.W. Lam, and A.C. Levine Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells J. International Du Cancer Int. J. Cancer 125 2009 774 782
219. A.J. Tervo, S. Kyrylenko, P. Niskanen, A. Salminen, J. Leppanen, T.H. Nyronen, T. Jarvinen, and A. Poso An in silico approach to discovering novel inhibitors of human sirtuin type 2 J. Med. Chem. 47 2004 6292 6298
220. I.H. Son, I.M. Chung, S.I. Lee, H.D. Yang, and H.I. Moon Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera Bioorg. Med. Chem. Lett. 17 2007 4753 4755
221. L.G. Wang, X.M. Liu, Y. Fang, W. Dai, F.B. Chiao, G.M. Puccio, J. Feng, D. Liu, and J.W. Chiao De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc Int. J. Oncol. 33 2008 375 380
222. D.H. Kim, J. Shin, and H.J. Kwon Psammaplin A is a natural prodrug that inhibits class I histone deacetylase Exp. Mol. Med. 39 2007 47 55
223. E. Lara, A. Mai, V. Calvanese, L. Altucci, P. Lopez-Nieva, M.L. Martinez-Chantar, M. Varela-Rey, D. Rotili, A. Nebbioso, S. Ropero, G. Montoya, J. Oyarzabal, S. Velasco, M. Serrano, M. Witt, A. Villar-Garea, A. Imhof, J.M. Mato, M. Esteller, and M.F. Fraga Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect Oncogene 28 2009 781 791
224. D. Desai, U. Salli, K.E. Vrana, and S. Amin SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 20 2010 2044 2047
225. C.M. Grozinger, E.D. Chao, H.E. Blackwell, D. Moazed, and S.L. Schreiber Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening J. Biol. Chem. 276 2001 38837 38843
226. R.C. Neugebauer, U. Uchiechowska, R. Meier, H. Hruby, V. Valkov, E. Verdin, W. Sippl, and M. Jung Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode J. Med. Chem. 51 2008 1203 1213
227. M.C. Myzak, P.A. Karplus, F.L. Chung, and R.H. Dashwood A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase Cancer Res. 64 2004 5767 5774
228. A. Schuetz, J. Min, T. Antoshenko, C.L. Wang, A. Allali-Hassani, A. Dong, P. Loppnau, M. Vedadi, A. Bochkarev, R. Sternglanz, and A.N. Plotnikov Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin Structure 15 2007 377 389
229. M. Gutierrez, E.H. Andrianasolo, W.K. Shin, D.E. Goeger, A. Yokochi, J. Schemies, M. Jung, D. France, S. Cornell-Kennon, E. Lee, and W.H. Gerwick Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula J. Org. Chem. 74 2009 5267 5275
230. S. Lain, J.J. Hollick, J. Campbell, O.D. Staples, M. Higgins, M. Aoubala, A. McCarthy, V. Appleyard, K.E. Murray, L. Baker, A. Thompson, J. Mathers, S.J. Holland, M.J. Stark, G. Pass, J. Woods, D.P. Lane, and N.J. Westwood Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 13 2008 454 463
231. P.H. Kiviranta, J. Leppanen, V.M. Rinne, T. Suuronen, O. Kyrylenko, S. Kyrylenko, E. Kuusisto, A.J. Tervo, T. Jarvinen, A. Salminen, A. Poso, and E.A. Wallen N-(3-(4-Hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors Bioorg. Med. Chem. Lett. 17 2007 2448 2451
232. J. Huang, C. Glass, and C. Gerhauser Cancer Chemoprevention by targeting the epigenome Curr Drug Targets 12 13 2011 1925 1956